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TCTAP A-006
Impact of Polypharmacy on Adherence to Evidence-based Medications in
Patients who Underwent Percutenous Coronary Intervention
Shaban Mohammed, Abdulrahaman Arabi, Ayman El-Menyar, Sabir Abdulkarim,
Ahmed Awaisu1, Awad Alqahtani, Khalid Al Siyabi, Tarek Aboughazala, Salah Arafa,
Amina Sadiq, Rajvir Singh, Jassim Al suwaidi
Heart Hospital, Hamad Medical Corporation, Doha, Qatar, 1College of Pharmacy,
Qatar university, Doha, Qatar
Background: The study primary aims to evaluate the impact of polypharmacy on
adherence to evidence-based medications (EBM) among patients who underwent
percutaneous coronary intervention (PCI) in Qatar.
Methods: We conducted a retrospective analysis for patients who underwent PCI at a
tertiary cardiac care hospital in Qatar. Patients who had polypharmacy (deﬁned as 6
medication or more) were compared with those who had no polypharmacy at hospital
discharge in term of adherence to dual antiplatelet therapy (DAP), beta-blocker (BB),
angiotensin converting enzyme inhibitors (ACEI), and statin used. Data were analyzed
and compared using Chi-square and student T test. Outcome was the adherence to the
ﬁrst reﬁll EBM.
Results: A total of 557 patients (85% male) who underwent PCI were included. The
mean age of the study population was 53.
Conclusion: In patients underwent PCI, polypharmacy at discharge could play a
negative role in the adherence to the ﬁrst reﬁll evidence based medications. Further
studies should investigate other parameters that contribute to long term non-adherence.
TCTAP A-007
High Dose Atorvastatin Improved Endothelial Progenitor Cells Mobilization in
Patients with Non-ST Elevated Acute Coronary Syndrome
Biao Xu, Jiaxin Ye, Jun Xie
Nanjing Gulou Hospital, Nanjing, China
Background: High dose statin can signiﬁcantly decrease the risk of recurrent major
cardiac events in patients with acute coronary syndromes (ACS), but the mechanisms
are still unclear. We hypothesized that the protective effect of high dose statin in ACS
worked through profoundly increasing EPCs mobilization and subsequent myocardial
neovascularization. Thereby we study the effects of high dose atorvastatin on EPCs
mobilization in patients, then in order to investigate the possible mechanism under-
lying the EPCs mobilization effects of high dose statins in mouse myocardial
infarction model, and thereby high dose statins exert beneﬁcial effects on myocardial
neovascularization, left ventricular function and remodeling.
Methods: From December 2010 to July 2011, patients with NSTEACS (n¼48)
scheduled for percutaneous coronary intervention were randomly given a standard
(20mg/d) or high dose atorvastatin (80mg/QN*2 days, then 40mg/QN*28 days) at
admission. Early human EPCs deﬁned as CD45low/-CD34+KDR+CD133+ cells were
dynamically counted by ﬂow cytometry. Cardiovascular evidences were follow-
upped. In addition to clinical trial, Wild-type C57BL /6 mice with acute anterior
myocardial infarction (AMI) were randomized to receive vehicle as control, or stan-
dard or high dose atorvastatin (high 15 mg/kg*day, standard 5 mg/kg*day) for 4
weeks by gavage after AMI. Early mouse EPCs deﬁned as c-Kit+FLK-1+Sca-1+ cells
were count by ﬂow cytometry. The plasma levels of vascular endothelial growth factor
(VEGF) and stromal cell-derived growth factor-1 (SDF-1) were determined by ELISA
both in patients and animal subjects. Phosphorylation of Akt/ protein kinase B (PKB)
and endothelial nitric oxide synthase (eNOS) in mouse bone marrow were assessed by
Western blotting analysis.
Results: Patients the enhanced mobilization of EPCs and increased plasma
VEGF levels in high dose atorvastatin were observed before PCI (P<0.01), while the
level of early EPCs and the levels of VEGF kept still in standard group. After the PCI,
the early EPCs in both two groups went up (P<0.05), but the level of early EPCs and
VEGF in high dose group was still higher than the standard group (P<0.01). And
there was a signiﬁcant positive relationship between the level of EPCs and VEGF at
day 2 (r¼0.77, P<0.01). And there were no different among the levels of SDF-1 and
hsCRP in these two groups at each time point (P>0.05).
Mice the same effect of high dose atorvastatin on EPC mobilization was observed in
animal models (all P<0.01). Under high dose atorvastatin treatment, left ventricular
dysfunction and interstitial ﬁbrosis were markedly improved in AMI mice (P<0.05).
Furthermore, the levels of phospho-Akt and phospho-eNOS were up-regulated in the
bone marrow of AMI mice (P<0.01).
Conclusion: Our ﬁndings suggested high dose atorvastatin enhanced the EPCs
mobilization in both NSTEACS patients and AMI mice. These effects may be
mediated through an increase in the plasma VEGF level as well as activation of PI-3K/
Akt/eNOS signaling pathway in bone marrow.JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/ORATCTAP A-008
Preventive Versus Culprit-only Percutaneous Coronary Intervention in ST-
elevation Myocardial Infarction Patients with Multivessel Disease: A Meta-
Analysis
Yeo-Jeong Song, Jae-Sik Jang, Joo-Il Yang, Ho-Young Lee, Han-Young Jin,
Jeong-Sook Seo, Tae-Hyun Yang, Dae-Kyeong Kim, Dong-Soo Kim
Busan Paik Hospital, Busan, Korea (Republic of)
Background: Only culprit vessel is proposed to be treated during primary percuta-
neous coronary intervention (PCI) in ST-segment elevation myocardial infarction
(STEMI) patients with multivessel coronary artery disease. However, the beneﬁts of
complete revascularization in patients with STEMI are still controversial.
Methods: Relevant studies published through September 2013 were searched and
identiﬁed in the electronic databases. Primary endpoint was all-cause mortality at the
longest follow-up. Secondary endpoints included myocardial infarction (MI), repeat
revascularization, and major adverse cardiac events (MACE). Summary estimates
were obtained using a random-effects model.
Results: From 836 initial citations, 5 randomized trials and 24 observational
studies with 43,960 patients (7,937 preventive and 36,023 culprit-only) were
included in this study. There were no signiﬁcant differences in all-cause mortality
(odds ratios [OR] 1.01, 95% CI 0.77 to 1.32; p <0.001), MI (OR 1.12, 95% CI
0.63 to 1.99, p ¼ 0.70), and repeat revascularization (OR 0.72, 95% CI 0.51 to
1.02; p ¼ 0.07) between the two groups. Comparison of preventive PCI versus
culprit-only PCI group disclosed ORs for MACE of 0.83 (95% CI 0.59 to 1.18; p
¼ 0.31). Sensitivity analysis suggested lower odds of repeat revascularization (OR
0.37, 95% CI 0.26 to 0.54; p<0.001) and MACE (OR 0.64, 95% CI 0.43 to 0.94; p
¼ 0.02) with preventive PCI in randomized trials compared with those in non-
randomized studies. However, stratiﬁed analysis according to the different strategy
demonstrated a signiﬁcantly lower incidence of all-cause mortality with staged PCI
compared with culprit-only or multivessel PCI during the index procedure
(Figure).
Conclusion: Current analysis of heterogeneous studies did not reveal any beneﬁt of
multivessel PCI over culprit-only PCI during index procedure or staged PCI in pa-
tients with STEMI. Further study is needed to clarify which PCI strategies will have
greater beneﬁt.TCTAP A-009
The Efﬁcacy of Everolimus-eluting Stent (EES) Implantation in Patients with
ST-elevation Myocardial Infarction: Outcomes of 2-year Clinical Follow-up
Hideki Yano1, Shigeo Horinaka2, Mayuko Ishikawa1, Toshihiko Ishimitsu2
1Nasu Red Cross Hospital, Tochigi, Japan, 2Dokkyo Medical University, Tochigi,
Japan
Background: Drug-eluting stents (DES) are increasingly used for treatment of acute
coronary syndrome (ACS), but there are few comparisons of outcomes of secondL/Acute Coronary Syndrome: STEMI, NSTE-ACS S3
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19th CardioVascular Summit: TCTAP 2014generation DES with long term outcomes. Our objective is to compare the efﬁcacy and
safety of the XIENCE V EES and the MULTI-LINK VISION cobalt chromium
stent (CCS) which has same platform in the setting of primary intervention for STEMI
patients.
Methods: Consecutive 338 patients with STEMI, who were treated with EES (162
patients) and CCS (176 patients). Within ten months angiographic follow-up results
and 2-year clinical follow-up outcomes were compared between 2 groups.
Results: The prevalence of diabetes and Chronic kidney disease were higher, the stent
length was longer (24.19.5 vs. 18.28.3, p<0.05), and late loss was smaller in EES
than in CCS group (0.250.24 vs. 0.550.33). However, the initial success rate was
similar between two groups. Follow-up data for 2-year, % binary restenosis (2.0 vs.
10.9%, p<0.05), TLR (2.0% vs. 9.7%, p<0.05), MI ( 0.7% vs.4.8%, p<0.05) and
stent thrombosis (0.7% vs. 4.2%, p<0.05) were signiﬁcantly higher in CCS than in
EES group.
Conclusion: EES implantation in patients with STEMI cases inhibited 2-year MACE
including TLR, MI and ST without increasing mortality compared with CCS
implantation.
TCTAP A-010
A Prospective, Observational, Multicenter Study Comparing Tenecteplase
Facilitated PCI Versus Primary PCI in Indian Patients with STEMI
(STEPP – AMI)
Suma Malini Victor1, Vijayakumar Subban1, Thomas Alexander2,
Bahuleyan C. Gopalan3, Arun Srinivas4, Selvamani Sethuraman5, Ajit S. Mullasari1
1Madras Medical Mission, Chennai, India, 2Kovai Medical Centre and Hospital,
Coimbatore, India, 3Ananthapuri Hospitals and Research Institute, Trivandrum,
India, 4Vikram Group of Hospitals, Mysore, India, 5Meenakshi Mission Hospital and
Research centre, Madurai, India
Background: Primary PCI in STEMI is the preferred treatment, but not a feasible
option for many and pharmacoinvasive therapy might be a practical solution in the
Indian context. The objective of this study is to assess the efﬁcacy of pharma-
coinvasive strategy in STEMI patients versus primary PCI.
Methods: This is an observational, multicenter study that prospectively enrolled 200
patients with STEMI. Patients who were ﬁbrinolysed (n¼45) formed arm ‘A’ and
underwent CAG within 3-24 hours with coronary intervention as appropriate. Arm ‘B’
consisted of patients who opted for primary PCI (n¼155). Primary endpoint was
composite of death, cardiogenic shock, reinfarction, repeat revascularization or
congestive heart failure up to 1 year.
Results: The IRA patency at angiogram was 82.2% in arm A and 22.6% in arm B
(‘p’ <0.001). PCI was performed in 73.3% Vs 100 % (‘p’<0.001), thrombus was
present in 26.7% Vs 63.2% (‘p’<0.001) in arms A & B respectively. Signiﬁcantly
more number of patients in arm A had TIMI 3 ﬂow in the culprit vessel at angio-
gram than arm B, 27.9% Vs 4.5% (‘p’ < 0.001). Failed ﬁbrinolysis occurred in
12.1%. Total ischemic time was 245 minutes (185-395) for arm A and 260 minutes
(185-390) for arm B. There was no difference in bleeding risk. Primary end
point occurred in 13.3% in arm A and in 9% in arm B, ‘p’¼ 0.40, (RR 0.64; 95% CI
0.24- 1.79).
Conclusion: Pharmacoinvasive strategy resulted in comparable outcomes as primary
PCI at 1 year. Larger RCTs are required to conﬁrm these ﬁndings.
TCTAP A-011
Prognostic Importance of Killip Classiﬁcation in Modern Pharmaco-invasive
Treatment Era for the Patients with Acute Myocardial Infarction (Report from
Mie ACS Registry)
Tairo Kurita1, Naoto Kumagai2, Kouzo Hoshino1, Tetsuya Seko2, Takafumi Koji2,
Katsutoshi Makino2, Jun Masuda2, Takashi Tanigawa2, Mashio Nakamura2,
Ito Masaaki2
1Nagai Hospital, Tsu, Japan, 2Mie CCU Network, Tsu, Japan
Background: During the last decades, as the treatment for acute myocardial infarction
(AMI) has been improved, in-hospital mortality of AMI has been decreased.
Accordingly, the purpose of this study was to ensure and reassess the importance of
Killip classiﬁcation in modern pharmaco-invasive treatment eracompared with other
common prognostic variables.
Methods: From January 2013 to July 2013, we analyzed information from 250 patients
with AMI in Mie CCU registry data. Mie CCU network was established for the early
pre-hospital care of patients with AMI and consecutive AMI patients was registered at
Mie CCU registry data. They were categorized to Killip 1, 2/3 (heart failure) and 4
(shock status). Multivariate cox proportional hazard models were developed to
determine the prognostic importance of killip classiﬁcation in comparison with other
variables. Primary end point of this study is deﬁned as all cause in-hospital mortality.
Results: Overall in-hospital mortality was 11.4%. Higher Killip classiﬁcation was
associated with higher in-hospital mortality (2.1% in Killip 1, 6.8% in 2/3, 45.9% in 4;
P<0.0001, See ﬁgure). According to the multivariate analysis, Killip classiﬁcation,
serum-creatinine and postrprocedural TIMI ﬂow were independent predictor for in-
hospital mortality. In addition, Killip classiﬁcation is the strongest independent pre-
dictor with hazard ratio of 7.3 compared to other factors.
Conclusion: Killip classiﬁcation is still powerful independent predictor for in-hospital
mortality. In comparison with the studies for the last several decades, in-hospital
mortality in patients with Killip 1 and 2/3 at modern treatment era was lower.S4 JACC Vol 63/12/Suppl S j April 22–25, 2014 jTCTAP A-012
The Protective Effect of Aspiration Thrombectomy on Side Branch Compromise
and Twelve Months Clinical Outcomes in AMI with Bifurcation Lesion
Undergoing Primary PCI
Ji Young Park, Jigyoung Park, Sungkee Rhy, Changsup Song
Eulji General Hospital, Seoul, Korea (Republic of)
Background: Bifurcation lesions (BF) remains a challenging lesion subset, often
associated with lower success rates. Side branch (SB) compromise in bifurcation
lesion is a major determinant of lower procedural success rates and adverse outcomes.
Aspiration thrombectomy (AT) prevent distal embolization in acute myocardial
infarction (AMI). The aim of this study is to evaluate the protective effect of AT on SB
compromise in BF lesions and twelve months clinical outcomes in AMI patients
undergoing primary percutaneous coronary intervention (PCI).
Methods: A total of 201 AMI patients with bifurcation lesion undergoing PCI were
analyzed between 2007 and 2011. The patients were divided into two groups ac-
cording to use of AT (AT group: n¼74, non AT group:n¼127).
We compared Thrombolysis In Myocardial Infarction (TIMI) of main and side
branch and 12 months clinical outcomes including mortality, reinfarction, target lesion
revascularization (TLR), and major adverse cardiac event (MACE) including mor-
tality, reinfarction, and TLR.
Results: Baseline clinical characteristics were similar between two groups. Angio-
graphic characteristics showed that LAD lesion was higher in non AT group (39.2%
vs 54.8%, p¼0.04) and RCA lesion was higher in AT group (45.9% vs 31.7%,
p¼0.050). Visible thrombus (94.6% vs 65.3%, p<0.001) and the use of GP IIb/IIIa
inhibitor (43.2% vs 27.6%, p¼0.030) was higher in AT group. PreTIMI was similar
between two groups. However, post TIMI 3 ﬂow was higher in AT group (94.4% vs
80.2%, p¼0.033). However, there were no difference of 12 months clinical outcomes
including mortality (5.4% vs 9.1%, p¼0.708), reinfarction (5.4% vs 12.1%, p¼0.324),
TLR (0.0% VS 3.0%, P¼535), and MACE (13.5% vs 28.8%, p¼0.093). Kaplan-
Meyer curve showed that the cumulative incidence of MACE was similar between two
groups (Log rank¼0.196)
Conclusion: In the present study, AT is related to post TIMI 3 ﬂow in AMI patients
with BF lesion undergoing primary PCI. However, cumulative incidence of MACE
was similar between two groups.TCTAP A-013
Prognostic Impact of Bundle Branch Block in Diabetic Patients with Acute
Myocardial Infarction
Doo Sun Sim1, Myung Ho Jeong1, Youngkeun Ahn1, Young Jo Kim2,
Shung Chull Chae3, Taek Jong Hong4, In Whan Seong5, Jei Keon Chae6,
Chong Jin Kim7, Myeong Chan Cho8, Seung-Woon Rha9, Jang Ho Bae10,
Ki Bae Seung11, Seung Jung Park12
1Chonnam National University Hospital, Gwanjgu, Korea (Republic of), 3Kyungpuk
National University Hospital, Daegu, Korea (Republic of), 4Busan National
University Hospital, Busan, Korea (Republic of), 5Chungnam National University
Hospital, Daejon, Korea (Republic of), 6Chunbuk National University Hospital,
Jeonju, Korea (Republic of), 7Kyung Hee University Hospital, Seoul, Korea (Republic
of), 8Chungbuk National University Hospital, Cheongju, Korea (Republic of),
99Korea University Guro Hospital, Seoul, Korea (Republic of), 10Konyang University
Hospital, Daejon, Korea (Republic of), 11Catholic University Seoul St. Mary’s
Hospital, Seoul, Korea (Republic of), 12Asan Medical Center, Seoul, Korea (Republic
of), 2Yeungnam University Hospital, Daegu, Korea (Republic of)
Background: The presence of bundle branch block (BBB) has been associated with
poor clinical outcome in patients with acute myocardial infarction (MI). BBB,
particularly left BBB, in diabetes mellitus (DM) may signify advanced cardiovascularTCTAP Abstracts/ORAL/Acute Coronary Syndrome: STEMI, NSTE-ACS
